Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 13649

Original article / research
Year : 2017 | Month : November | Volume : 11 | Issue : 11 | Page : OC05 - OC09

A Comparative Evaluation of Ramipril as Monotherapy and Combination of Ramipril with Torsemide in Hypertension

Navjot Kaur, Ravinder Garg, Jasleen Kaur, Kamal Preet Palta, Mala Chandra, Shaminder Kaur, Ranabir Pal

1. Postgraduate Resident, Department of Pharmacology, GGS Medical College, Faridkot, Punjab, India. 2. Professor and Head, Department of Medicine, GGS Medical College, Faridkot, Punjab, India. 3. Professor and Head, Department of Pharmacology, GGS Medical College and Hospital, Faridkot, Punjab, India. 4. Associate Consultant, Department of Emergency Medicine, Max Smart Hospital, Delhi, India. 5. Postgraduate Resident, Department of Pharmacology, GGS Medical College and Hospital, Faridkot, Punjab, India. 6. Associate Professor, Department of Medicine, GGS Medical College and Hospital, Faridkot, Punjab, India. 7. Professor and Head, Department of Community Medicine, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair, Andaman and Nicobar Islands, India.

Correspondence Address :
Dr. Ravinder Garg,
Professor and Head, Department of Medicine, GGS Medical College and Hospital, Faridkot-151203, Punjab, India.
E-mail: drravindergarg@gmail.com

Abstract

Introduction: A Fixed-Dose Combination (FDC) of antihypertensive agents of different groups might offer advantages of efficacy, tolerability and compliance over monotherapy.

Aim: To compare efficacy and tolerability of ramipril/torsemide FDC with ramipril monotherapy.

Materials and Methods: This prospective open labeled randomized comparative study was conducted on newly diagnosed 100 patients, suffering from primary hypertension. They were divided in two groups viz., Group A (Ramipril 5 mg/day) and Group B (Ramipril 5 mg with Torsemide 5 mg/day). The study drugs were prescribed for a period of 12 weeks. To find comparative efficacy, the primary goal BP was set at less than 140 mmHg systolic and 90 mmHg diastolic blood pressure. Haematological and biochemical assessments were embedded in the methods at baseline and at the end of study. All the participants were evaluated for dyselectrolytemia, Blood urea, Serum Creatinine, and lipid profile during the study period at baseline and three follow ups at 4th, 8th and 12th weeks along with recording of adverse drug reactions. To assess tolerability of both regimens, the participants were interviewed followed by physical examination and laboratory investigation.

Results: The participants on FDC therapy (ramipril and torsemide) had shown significant reduction in ambulatory and office-measure BP compared to the participants on monotherapy (ramipril) with Stage I and Stage II hypertension. The goal BP was achieved with combination therapy in 4 weeks compared to monotherapy that was achieved in eight weeks. In the safety profiles, mild adverse drug reactions were reported with both the therapies.

Conclusion: FDC treatment showed significant fall in systolic BP after 4 weeks and diastolic BP after 12 weeks compared to the monotherapy while both the regimens were well tolerated.

Keywords

Angiotensin converting enzyme, Dyselectrolytemia, Fixed-dose combination

How to cite this article :

Navjot Kaur, Ravinder Garg, Jasleen Kaur, Kamal Preet Palta, Mala Chandra, Shaminder Kaur, et al.. A COMPARATIVE EVALUATION OF RAMIPRIL AS MONOTHERAPY AND COMBINATION OF RAMIPRIL WITH TORSEMIDE IN HYPERTENSION. Journal of Clinical and Diagnostic Research [serial online] 2017 November [cited: 2018 Jan 17 ]; 11:OC05-OC09. Available from
http://www.jcdr.net/back_issues.asp?issn=0973-709x&year=2017&month=November&volume=11&issue=11&page=OC05-OC09&id=10819

DOI and Others

DOI: 10.7860/JCDR/2017/24715.10819

Date of Submission: Oct 15, 2016
Date of Peer Review: Dec 10, 2016
Date of Acceptance: Jul 15, 2017
Date of Publishing: Nov 01, 2017

FINANCIAL OR OTHER COMPETING INTERESTS: None.

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2016: 132.37
  • SCOPUS
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • EBSCOhost
  • Embase & EMbiology
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com